Clinical Trial Update: A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating oral upadacitinib in adults and adolescents with moderate-to-severe hidradenitis suppurativa who failed anti-TNF therapy; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Upadacitinib (Rinvoq) (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Hidradenitis Suppurativa | Phase 3 | Status: RECRUITING